Type 2 Diabetes Mellitus: From Metabolic Dysfunction Syndrome to Precision Prevention and Targeted Therapy

Putri Karenina Amalia Wulandari; Dhiny Sylvana; Suandy Suandy

doi:10.30872/jtpc.v10i2.439

Authors

Putri Karenina Amalia Wulandari Faculty of Medicine, Universitas Prima Indonesia, Medan, Indonesia Author
Dhiny Sylvana Department of Internal Medicine, Faculty of Medicine, Universitas Prima Indonesia, Medan, Indonesia Author
Suandy Suandy Department of Clinical Medicine, Universitas Prima Indonesia Author

DOI:

https://doi.org/10.30872/jtpc.v10i2.439

Keywords:

type 2 diabetes mellitus, Metabolic dysfunction syndrome, Chronic inflammation, Inter-organ crosstalk, Precision medicine

Abstract

Type 2 diabetes mellitus (T2DM) remains a prevalent metabolic disorder worldwide, continuously imposing
a substantial clinical and socioeconomic burden. Traditionally viewed as a glucose-centered disease
characterized by hyperglycemia driven by insulin resistance and pancreatic beta-cell dysfunction, recent
evidence clearly indicates that hyperglycemia is merely a downstream manifestation of broader metabolic
abnormalities. Advances in molecular biology, immunometabolism, and systems biology have facilitated the
emergence of Metabolic Dysfunction Syndrome (MDS) as a comprehensive framework for understanding
T2DM pathogenesis. This review summarizes the interconnected roles of insulin resistance, adipose tissue
dysfunction, ectopic lipid accumulation, chronic low-grade inflammation, oxidative stress, mitochondrial
dysfunction, progressive beta-cell failure, and inter-organ crosstalk in disease progression. Furthermore, we
extensively discuss the vital clinical implications of this paradigm shift, highlighting the critical importance of
early risk stratification, prescreening, timely diagnosis, and personalized therapeutic algorithms extending
beyond mere glycemic control. Emerging pharmacological therapies with cardiometabolic and renoprotective
benefits, combined with holistic lifestyle interventions, firmly support a vital transition from
reactive glucose-lowering strategies to proactive disease-modifying approaches targeting underlying
metabolic dysfunction. Ultimately, adopting the MDS framework provides a highly integrated understanding
of T2DM, directly offering unprecedented opportunities for precision prevention, individualized treatment,
and improved long-term clinical outcomes globally for all affected patients.

Downloads

Download data is not yet available.

References

[1.] Kementerian Kesehatan Republik Indonesia. 2018. Profil Penyakit Tidak Menular Tahun 2018. Kemenkes RI. Jakarta.

[2.] Balitbangkes. 2013. Laporan Hasil Riset Kesehatan Dasar Riskesdas Nasional. Jakarta: Depkes RI.

[3.] Frodermann, V., van Duijn, J., van Pel, M. et al., 2015. Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development. Sci Rep 5, 15559. https://doi.org/10.1038/srep15559.

[4.] Li Hanyue, Dai Hongwei, Li Jie. 2023. Immunomodulatory properties of mesenchymal stromal/stemcell : The link with methabolism. Journal of Advanced Research. 45; 15-29. doi: 10.1016/j.jare.2022.05.012.

[5.] Huang, Y., Wang, J., Cai, J., Qiu, Y., Zheng, W., and Liu, P. 2020. Hyperlipidemia impairs the regenerative potential of mesenchymal stem cells: mechanisms and implications for therapy. Stem Cells International, 8889763. https://doi.org/10.1155/2020/8889763.

[6.] Takada, S., Uyama, T., Okumoto, K., Kondo, M., & Murakami, M. 2017. Impact of dyslipidemia on mesenchymal stem cell function in regenerative medicine. Biochemical and Biophysical Research Communications, 493[2], 1063–1068. https://doi.org/10.1016/j.bbrc.2017.09.032.

[7.] Gharibi, T., Ahmadi, M., Seyfizadeh, N., Jadidi-Niaragh, F., and Yousefi, M. 2016. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis. Cellular Immunology, 310, 1–10. https://doi.org/10.1016/j.cellimm.2016.08.009.

[8.] Putra, A., Widyatmoko, A., Ibrahim, S., Amansyah, F., Amansyah, F., Berlian, M. A., ... & Rachmad, B. (2021). Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. F1000Research, 10, 228.

[9.] Rone, M.B., Fan, J., Papadopoulos, V. 2009. Cholesterol transport in steroid biosynthesis: Role of protein-protein interactions and implications in disease states. Biochim. Biophys. Acta, 1791, 646–658. doi: 10.1016/j.bbalip.2009.03.001.

[10.] Miller, W.L., Auchus, R.J. 2011. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev., 32, 81–151.

[11.] Utami, A., Putra, A., Wibowo, J. W., Amalina, N. D., & Satria Irawan, R. C. (2023). Hypoxic secretome mesenchymal stem cells inhibiting interleukin-6 expression prevent oxidative stress in type 1 diabetes mellitus. Medicinski glasnik, 20[2].

[12.] Taylor, M., Halicki, M., and Chazot, P. 2026. Cholesterol in Mitochondrial Diseases—Friend or Foe? International Journal of Molecular Sciences, 27[10], 4353. doi: https://doi.org/10.3390/ijms27104353.

[13.] Goicoechea, L., Conde de la Rosa, L., Torres, S., Garcia-Ruiz, C., Fernandez-Checa, J.C. 2023. Mitochondrial cholesterol: Metabolism and impact on redox biology and disease. Redox Biol., 61, 102643. doi: 10.1016/j.redox.2023.102643.

[14.] Holven, K. B., and Roeters van Lennep, J. 2023. Sex differences in lipids: A life course approach. Atherosclerosis, 384. doi: https://doi.org/10.1016/j.atherosclerosis.2023.117270.

[15.] Azzahara, S. Y., Agustina, R., & Prawitasari, S. (2023). Therapeutic Potential of Secretome-Derived Wharton's Jelly Mesenchymal Stem Cells in Psoriasis Vulgaris: A Case Study. International Journal of Cell and Biomedical Science, 2[5], 160-166.

[16.] Levy, D., Jeyaram, A., Born, L. J., Chang, K. H., Abadchi, S. N., Wei Hsu, A. T., ... & Jay, S. M. (2022). The Impact of Storage Condition and Duration on Function of Native and Cargo-Loaded Mesenchymal Stromal Cell Extracellular Vesicles. BioRxiv, 2022-06. doi: https://doi.org/10.1101/2022.06.14.496108.

[17.] Dominici, M. L. B. K., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., ... & Horwitz, E. M. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. doi: Cytotherapy, 8[4], 315-317. DOI: 10.1080/14653240600855905.

[18.] Le, J., Zhongqun, L., Zhaoyan, W., Yijun, S., Yingjin, W., Yaojie, W., ... & Xiaodan, S. 2021. Development of methods for detecting the fate of mesenchymal stem cells regulated by bone bioactive materials. Bioactive Materials, 6[3], 613-626. doi: https://doi.org/10.1016/j.bioactmat.2020.08.035.

[19.] Valle, A. C. V., Brunel, H. D. S. S., Dallago, B. S. L., Rodrigues, L. S., Malard, P. F., da Costa, R. A., & de Andrade, R. V. (2023). In-vitro growth kinetics of mesenchymal stem cells in cytotoxicity tests using low-diluted Viscum album. Homeopathy, 112(01), 040-049. doi: 10.1055/s-0042-1747682.

[20.] Palmisano, B. T., Zhu, L., & Stafford, J. M. 2017. Role of Estrogens in the Regulation of Liver Lipid Metabolism. In Adv Exp Med Biol. Vol. 1043, pp. 227–256. Doi: https://doi.org/10.1007/978-3-319-70178-3_12.

[21.] Rahmawati, Y., Rahmawati, F., and Perwitasari, E. 2022. Hiperkolesterolemia Pada Pasien Lanjut Usia : Studi Kasus Puskesmas Seyegan. Jurnal Kesehatan Tumbusai. Vol.3, No.1. doi: https://doi.org/10.31004/jkt.v3i1.3966.

[22.] AA Intan Pramesti, Premayani Sidemen, Suma Wirawan, Kadek Nova Adi Putra. “An Exploratory Study of the Prevalence and Risk Factors of Hypercholesterolemia Among the Elderly in Kelating Village, Tabanan Regency”. Jurnal Sehat Indonesia (JUSINDO). 7[2]:953-961. May 2025, doi: :10.59141/.v7i2.368.

[23.] Lin, Y.-H.; Kang, L.; Feng, W.-H.; Cheng, T.-L.; Tsai, W.-C.; Huang, H.-T.; Lee, H.-C.; Chen, C.-H. 2020. Effects of Lipids and Lipoproteins on Mesenchymal Stem Cells Used in Cardiac Tissue Regeneration. Int. J. Mol. Sci. 21, 4770. https://doi.org/10.3390/ijms21134770.

[24.] Sohn, J., Lin, H., Fritch, M.R. 2018. Influence of cholesterol/caveolin-1/caveolae homeostasis on membrane properties and substrate adhesion characteristics of adult human mesenchymal stem cells. Stem Cell Res Ther. 9, 86. https://doi.org/10.1186/s13287-018-0830-4.

[25.] Nugraha, D. K., & Falah, A. (2024). In Vitro Transcription as a Strategy to Enhance Mesenchymal Stem Cell Secretome for Therapeutic Use: An Overview. International Journal of Cell and Biomedical Science, 3[9], 270-281.

[26.] Nugraha, D. K., Anggoro, N. S., Sari, F. N., & Ardani, Y. (2025). Human-Umbilical Cord-Mesenchymal Stem Cells (hUC-MCSs) Therapy with Extravesicles (EVs) Booster Improves Recovery in Type 2 Diabetes Mellitus with Cardiovascular Disease. International Journal of Cell and Biomedical Science, 4[10], 318-323.

[27.] Turinetto, V., Vitale, E., and Giachino, C. 2016. Senescence in human mesenchymal stem cells: Functional changes and implications in stem cell-based therapy. International Journal of Molecular Sciences. 17[7]:1164. doi: 10.3390/ijms17071164.

[28.] Li X, Li Y, Yu H, Men LL, Deng G, Liu Z, Du JL. Oxidized Low-Density Lipoprotein Decreases the Survival of Bone Marrow Stem Cells via Inhibition of Bcl-2 Expression. Tissue Eng Part A. 2025. Apr;31(7-8):325-333. doi: 10.1089/ten.TEA.2024.0025. Epub 2024 Jun 27. PMID: 38818810.

[29.] Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. 2002. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 106:2067–2072. doi: 10.1161/01.cir.0000034509.14906.ae.

[30.] Sun Q, Li J, Gao F. 2014. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J Diabetes.15;5[2]:89-96. doi: 10.4239/wjd.v5.i2.89. PMID: 24765237; PMCID: PMC3992527.

[31.] Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL, Lian Q. 2016. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 21;7[1]:e2062. doi: 10.1038/cddis.2015.327. PMID: 26794657; PMCID: PMC4816164.